Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
about
Sulfur dioxide inhibits vascular smooth muscle cell proliferation via suppressing the Erk/MAP kinase pathway mediated by cAMP/PKA signaling.Ras-dependent ERK activation by the human G(s)-coupled serotonin receptors 5-HT4(b) and 5-HT7(a).The expression of the thyroid-stimulating hormone (TSH) receptor and the cAMP-dependent protein kinase RII beta regulatory subunit confers TSH-cAMP-dependent growth to mouse fibroblasts.CNK1 is a scaffold protein that regulates Src-mediated Raf-1 activation.Potentiation of carbachol-induced detrusor smooth muscle contractions by beta-adrenoceptor activation.JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression.GNAS1 T393C polymorphism and disease progression in patients with malignant melanoma.Protein kinase A-mediated CREB phosphorylation is an oxidant-induced survival pathway in alveolar type II cellsTargeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis.MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells.Galectin-8 induces apoptosis in Jurkat T cells by phosphatidic acid-mediated ERK1/2 activation supported by protein kinase A down-regulation.Ras-mutant cancer cells display B-Raf binding to Ras that activates extracellular signal-regulated kinase and is inhibited by protein kinase A phosphorylation.Increased mitogen-activated protein kinase kinase/extracellularly regulated kinase activity in human endometrial stromal fibroblasts of women with endometriosis reduces 3',5'-cyclic adenosine 5'-monophosphate inhibition of cyclin D1.NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.Could radiotherapy effectiveness be enhanced by electromagnetic field treatment?Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling.A Raf-1 mutant that dissociates MEK/extracellular signal-regulated kinase activation from malignant transformation and differentiation but not proliferation.Integrated modulation of phorbol ester-induced Raf activation in EL4 lymphoma cells.Cyclic AMP inhibits the proliferation of thyroid carcinoma cell lines through regulation of CDK4 phosphorylation.DeltaRaf-1:ER* bypasses the cyclic AMP block of extracellular signal-regulated kinase 1 and 2 activation but not CDK2 activation or cell cycle reentry.Raf-1 serine 338 phosphorylation plays a key role in adhesion-dependent activation of extracellular signal-regulated kinase by epidermal growth factor.CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation.CUTL1 is phosphorylated by protein kinase A, modulating its effects on cell proliferation and motility.Activation of FoxO transcription factors contributes to the antiproliferative effect of cAMP.Cyclin D1 and cyclin D3 show divergent responses to distinct mitogenic stimulation.Differential regulation of mesangial cell mitogenesis by cAMP phosphodiesterase isozymes 3 and 4.Novel C-Raf phosphorylation sites: serine 296 and 301 participate in Raf regulation.In silico pharmacology suggests ginger extracts may reduce stroke risks.Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites.PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.Protein Kinase A Intersects Src Signaling in Membrane Microdomains
P2860
Q33720170-E3AE1EE2-1760-4B58-9ECE-A10F64B5341EQ34160428-3ED29879-F904-44EF-9DA8-EEE08110862CQ34220128-FCB84F87-652F-40C5-B72D-784336532F65Q34413075-749AB95A-647D-4C5A-9987-D3EAEAFF8125Q35381711-4D2E72A5-CF55-40C5-968D-858D43FA9122Q35635353-0D222803-1330-474F-B0FB-B453687D0C77Q35688212-75223561-F52D-4B43-A7A2-54641737E7EAQ35959897-FDBF0465-287D-4F5A-914A-AFA23A9DED02Q36558150-23D31167-996E-42DA-B260-90051AAD493CQ36804407-20DCD691-09B2-4100-990E-D5B53F84A341Q37117708-8E133B04-F1AE-4C32-B62B-4EE4376C4885Q37176373-49123D76-A97A-40A4-A4BB-677C59ABF9FCQ37189612-ECB4BD95-4397-42F4-A29A-E7CED2838647Q37369106-E4E752BB-C63A-4CC4-8247-F5BAE190335CQ37689575-8F53B94D-AFC5-4FC2-9F88-2AE3A0C218B6Q38122586-892A378E-3E00-4C63-98B3-A37FDF4943C2Q39665762-692202C7-B24C-4AE7-9B3B-CB3060BC2051Q39732365-68451F8B-811E-4006-8EC5-F61E18F686CDQ39876900-C7A7C6DE-5F08-487C-9D00-1644B2C773F1Q39938669-0017304E-5D06-405F-B2C6-802642BDC5ADQ40408138-356D5086-A82C-4886-81D0-9FC467E28610Q40421041-13DFA48A-19E7-4FDC-A923-BB22846E7020Q41825679-6080B69E-64B7-4BE9-9DE8-4F2A04628AC0Q42803832-9F458081-D153-46A3-9420-283FD3162BB5Q42818558-B6C25C96-DE62-4DB1-9CB4-33EED6A15728Q42826838-0D3521F2-1FF6-48FE-BC5B-31FF8E50F9ACQ44997546-8088AADD-0861-4179-A655-D56D2E19BD4CQ45218398-8CC9F15A-58F3-434F-A510-4576EAF21D9BQ45961735-B388D789-4DB3-48A4-AB83-539AC4235B14Q46458312-D73CB28D-2AAA-4B84-AE0E-3E57466144D3Q51188245-4919CF68-151F-40E0-B2DE-8ED2306AB6ECQ57372111-BD4046E9-E3A2-4B4A-A8B3-6C79EE77085A
P2860
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
@en
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
@nl
type
label
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
@en
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
@nl
prefLabel
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
@en
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
@nl
P2860
P1476
Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.
@en
P2093
Nicolas Dumaz
Yvonne Light
P2860
P304
P356
10.1128/MCB.22.11.3717-3728.2002
P407
P577
2002-06-01T00:00:00Z